Retargeted Oncolytic Measles Strains Entering via the EGFRvIII Receptor Maintain Significant Antitumor Activity against Gliomas with Increased Tumor SpecificityCory Allen, Evanthia Galanis, Sompong Vongpunsawad et al.|Cancer Research|2006Cited by 106
Supplementary Figure 1 from Retargeted Oncolytic Measles Strains Entering via the EGFRvIII Receptor Maintain Significant Antitumor Activity against Gliomas with Increased Tumor SpecificityCory Allen, Evanthia Galanis, C. David James et al.|Unknown|2023Cited by 0
Supplementary Figure Legend from Retargeted Oncolytic Measles Strains Entering via the EGFRvIII Receptor Maintain Significant Antitumor Activity against Gliomas with Increased Tumor SpecificityCory Allen, Evanthia Galanis, Sompong Vongpunsawad et al.|Unknown|2023Cited by 0
Supplementary Figure 1 from Retargeted Oncolytic Measles Strains Entering via the EGFRvIII Receptor Maintain Significant Antitumor Activity against Gliomas with Increased Tumor SpecificityCory Allen, Evanthia Galanis, Sompong Vongpunsawad et al.|Unknown|2023Cited by 0
Data from Retargeted Oncolytic Measles Strains Entering via the EGFRvIII Receptor Maintain Significant Antitumor Activity against Gliomas with Increased Tumor SpecificityCory Allen, Evanthia Galanis, Sompong Vongpunsawad et al.|Unknown|2023Cited by 0